- Multiple System Atrophy (MSA) is a rare, relentlessly progressive and fatal neurodegenerative disease
- Verdiperstat is a potential first-in-class, brain-penetrant inhibitor of myeloperoxidase (MPO), an enzyme implicated in neuroinflammation and neurodegeneration
- Approximately 300 patients enrolled in the 48-week trial and topline data anticipated by the end of 2021
PR Newswire
NEW HAVEN, Conn., July 21, 2020